---------- - 1 -
----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 -
Q14 17 Q15 17 Q16 18 Q17 18 Q18? 18 Q19 19 20 Q20 20 Q21 20 Q22 21 Q23 21 Q24 22 Q25 22 Q26 22 Q27 23 Q28 NAT 25 Q29 26 Q30 HBs 27 Q31 27 29 Q32 29 Q33 29 Q34 29 Q35 30 Q36 31 Q37 31 HBV 33 Q38 33 Q39 33 Q40 34 Q41 34 Q42 35 Q43 35 Q44 35-3 -
Q45 35 37 Q46 37 Q47 37 Q48 37 Q49 38 Q50 38 Q51 38 Q52 38 40 Q53 40 Q54 40 Q55 HB 41 Q56 _ 41 42 Q57 42 Q58 42 44 Q59 44-4 -
Q1 Q2 HBV HBV Q3-5 -
HBs HBIG HB Q34 HBV Q4 HBV HBs HBc 11 (1999 )10 Nucleic acid Amplification Test NAT HBV DNA 10 NAT HBV DNA 6 Q27 Q28 Q5-6 -
HBV Q6 HBs ( ) HBs HBs HBV Q7 2 HBV Q8-7 -
HB HBs HBIG Q30 Q31 Q9 HBV 10 15 HBV 10 15% ALT GPT HBV Q10-8 -
- 9 -
Q1 B HBV 20 HBV HBV HBV HBV HBV 2 HBV HBV HBV A 10 HBV HBV HBV HBV - 10 -
HBV HBV HBV HBV 10 15 HBV 10 15 ALT GPT HBV 50 HBV Q2 HBV B HBV HBV HBV HBV HBV Q3 (HBV) HBV HBV HBV HBV HBV HBV HBV - 11 -
Q4 (HBV) HBV HBs HBs HBV HBV HBV HBV Nucleic acid Amplification Test: NAT HBV Q8 Q5 B HBV HBs HBc HBV 42nm 1nm 1m 10 1 DNA DNA DNA DNA nucleocapsid 27nm envelope HBV HBs HBc HBV HBV HBs 22mm HBV HBV 1 500 1,000 50 100 HBc HBV Q6 HBV HBe HBe HBV HBV HBV HBe HBV HBe HBe - 12 -
HBe HBV HBV HBe HBe HBe HBV Q7 HBV HBV HBs HBs HBc HBc HBe HBe HBV HBV HBV 1 HBs Q5 2 HBs HBs HBV HBs HBV HBs HBs HBs HBV 3 HBc HBc HBV HBV HBV HBV HBV HBc HBe HBV - 13 -
4 HBc HBc HBV HBc HBc HBV HBV HBc HBs IgM HBc IgG HBc IgM HBc HBc HBs HBs HBc HBs HBV NAT HBV Q27 NAT Q8 5 HBe HBe HBV HBe HBV HBV HBe HBV HBe HBV HBV HBV HBe 6 HBe HBe HBe HBe HBV HBV HBs HBe HBe HBV HBV HBe HBe HBe HBe - 14 -
HBV HBV HBV HBe 10 30 HBe HBe Q8 NAT Nucleic acid Amplification Test NAT 1 PCR(Polymerase chain reaction) HBV HBV NAT HBV DNA HBV HBs HBs HBs HBc HBV Q27, 28 NAT HBV DNA HBV Q9 HBV HBV HBV HBV HBV Q7 HBV HBV DNA HBV Q10 HBV (HBV) - 15 -
HBV Q11 HBs HBs 59 HBs Shreiber G B N. Engl. J. Med. 1996 10 7 ml 1 HBs 1 1ml HBs 3 51 HBs HBs HBV HBV DNA 10 HBV A 80 100 HBs Q27 Q12 HBV DNA 34 HBV DNA Shreiber G B N. Engl. J. Med. 1996 HBs HBV HBV DNA HBV HBV DNA 10 HBV A 55 70 HBV DNA - 16 -
10 2 /ml Q27 Q13 HBV HBV a 14 (2002 ) 40 Q15 b HBV c d e f HBV HBV Q14 HBV HBV C Q15-17 -
Q16 Q17 HIV (2001 ) HBs HCV (2006 ) HBs HCV Q18 HBV HBs HBV - 18 -
HBs HBV HBV HBV IgM HBc HBV HBc HBV HBs HBc B Q19 1 HBV HBe HBe HBV 2 AST GOT ALT GPT CT MRI - 19 -
Q20 B HBV HBV HBV HBV HBV HBV HBV HBV HBV HBV HBV Q21 B HBV HBV HBV HBV C HCV HIV HBV 1970 HBV HBV 1986-20 -
HBV HBV Q37 HBV HBV HBV HBV 10 HIV HBV Q22 HBV HBe HBV HBV HBV HBV HBs HB HBe HBV HBV HBs HBs HBs HB Q31 Q23 HBV HBV 1 2 3 4 5-21 -
Q24 HBV HBV 703 4 HBV 703 18 HBV HBV HBV HBV Q23 HBV Q25 HBV HBV Q26 B HBV HBs HBc 1999 10 Nucleic acid Amplification Test:NAT NAT HBV DNA 10 HBV HBV HBV NAT HBV NAT NAT - 22 -
HBV HBV HCV HIV 3 HBV HBV HBV HBV HBc HBV HBV HIV HBV HCV NAT HBV DNA 6 NAT HBV Q27 Q28 Q29 Q27 (HBV) HBV (NAT) HBV HBV 1 HBV HBV 35 5 HBV DNA 59 8.4 HBs Shreiber GB N. Engl. J. Med, 1996 HBs HBs HBV Q11 HBV HBV DNA 10 HBV HBV - 23 -
DNA HBV HBV HBV NAT HBV DNA 10 2 /ml HBV DNA 55 70 20 20 mini-pool NAT HBV DNA 10 3 /ml HBV DNA 65 80 EIA HBs 80 100 HBV NAT HBV DNA 100 2 HBV HBs HBc HBs HBV HBV HBV HBV - 24 -
HBV Uemoto S, et al. Transplantation. 1998, Murasawa H, et al. Hepatology 2000. HBV B NAT HBV DNA Q28 NAT 500 1 NAT 500 NAT 1999 7 2000 1 2,140,207 19 HBV 8 HCV NAT 500 50 (50 NAT)2000 2 2004 7 24,702,784 HBV HCV HIV 473 72 8 2004 8 20 NAT 2005 12 6,994,084 HBV HCV HIV 133 13 4 (HBV HCV HIV) (HBs HBc HCV HIV ) NAT - 25 -
NAT 20 NAT HBV HBV NAT HBV DNA Q27 HBV HCV HIV Q29 6 HBV 1989 11 HBs HBc B B 1999 10 NAT NAT HBV DNA 10 2 ml HBV NAT HBV 10 HBV HBV NAT HBV C HCV HIV - 26 -
Q30 HBs HBIG HBV HBs HBs HBs HBIG HBIG 1 200IU HBs HBIG HBIG HBs 48 HBV 1 HBV 2 HBV HBV HBIG 48 HBIG 2 1 2 Q31 HB HBV HB HBs HB HB HBs 1 10 3 4 5 1 HBs HBV 1/2 Q34-27 -
HB HB HBs 95 HB HBs HBV HBV HB HB HBs - 28 -
Q32 HBV HBV HBV HBs HBs HBV HBs 19 0.23 20 29 0.52 30 39 0.84 HBs HBe HBe Q34 Q33 HBV HBe HBV HBV 100 HBV 85 90 HBe 10 15 HBV 2 3 HBe HBV HBV 95 97 HBe HBV HBV HBV Q34 Q34 HBV HBV HBs HBIG HB HBe HBV HBe HBV - 29 -
HBV HBIG 48 HBe HBV HBs HBIG HB HBe 95 97 Q35 HBV HBV HBV HBs HBIG - 30 -
HB HBV HBV Q36 HBV HBV Q34 HBV 3 HB 6 HBV HBV 1 HBs 2 HBV Q37 HBV HBV 3 1) 1980 2) (1981 1985 ) 3) (1986 ) HBs HBV HBs HBV 1) 2) 3) HBs 0.20%(7/3,446) 0.16%(77/46,993) 0.01%(2/23,792) 1/20 HBs 0.96%(33/3,446) 0.55%(260/46,993) 0.21%(51/23,792) 1/4 Noto H. J. Gastroenterol. Hepatol. 2003 1) 2) 3) HBs 0.75%(78/10,437) 0.22%(46/20,812) 0.04%(12/32,049) HBs 1.52%(159/10,437) 0.79%(165/20,812) 0.85%(32/32,049) HBs HBc 1) 2) 3) 81.9%(127/155) 43.3%(68/157) 11.0%(59/536) Koyama T. Hepatology Research, 2004-31 -
HBV - 32 -
HBV Q38 HBV HBV HBV 10 15% HBV B 1 1 2 3 1 2 3 4 5 6 HBV HBV Q39 HBV HBV HBV HBV 10 30 85 90 HBV HBV 10 15-33 -
Q40 HBV HBV HBV HCV AST(GOT) ALT(GPT) 1 AST ALT Q41 HBV HBV 2 3-34 -
Q42 HBV HBV HBV 10 15% 2 3 http://www.jsh.or.jp/ Q43 B HBV HBV Q44 B HBV HBV Q45 B HBV 1995 2000 6-35 -
348.6 2000 HBs 16 19 0.23 20 29 0.52 30 39 0.84 40 49 1.19 50 59 1.50 60 69 1.27 2000 15 69 9,332.6 86.6 103.1 HBV HBV 1986 HBV 0.04 116-0033 3-6-21-201 TEL 03-5982-2150 10:00 16:00 FAX 03-5982-2151 URL http://members.at.infoseek.co.jp/sin594/ E-mail s-nisimu@sannet.ne.jp 156-0043 1-12-3-102 TEL 03-3323-2260 13:00 17:00 FAX 03-3323-2287 URL http://www.geocities.co.jp/colosseum-acropolis/9112/ E-mail zenkanren@geocities.co.jp - 36 -
Q46 HBV Q47 B HBe ALT HBe Q48-37 -
Q49 HBV ALT ALT 88 86 83 ALT ALT Q50 Q51 HBV HBV Gionotti HBV HBe Q52 1 72,300 139,800 1% - 38 -
35,400-39 -
Q53 B (HBV) HBV HBs HBe HBe HBs HBV HBs HBe HBe B HB ) HBV HBs HBs HB Q54 B (HBV) HBs HBV HBs HBs HBs (HBIG) 48 HBV HBe HBe HBe B (HBIG) HB Q31 HBV (HBs HB HBV (HBs HBe HBIG HB - 40 -
HBIG 48 HBIG 1 1980 HBe 167 133 80 34 20 HBV HBe HBe 675 100 48 HBIG HB HBe Q55 HB HBV HB HBs HBs HBs HB HBs HB HB Q31 HB HBs Q56 Q56 (HBV HBV HBV HBV - 41 -
Q57 B (HBV) HBV 1980 HBe HBV HBV 1981 HBV HBV HBV HBV HBV HBV Q58 B (HBV HBV - 42 -
15 1,000ppm 1 1,000ppm 5 6 50 60 2 HBV - 43 -
Q59-44 -
1. 21 2001 12 2 2003 3 3 2005 3 4 2004 3 2005 3 5 2000 6 2 2002 3 7 HBV 4 2003 3 8. Uemoto S, et al., Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants (Transplantation, 65: 494-499, 1998) 9. Murasawa H, et al., Latent hepatitis B virus infection in healthy individuals with antibody to hepatitis B core antigen (Hepatology, 31: 488-495, 2000) 10. Noto H, et al., Combined passive and active immunoprophylaxis for preventing peronatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980-1994 (J. Gastroenterol, Hepatol., 18:943-949, 2003) 11. Koyama T et al., Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylacxis in Iwate, Japan (1981-1992) and epidemiological evidence for its efficacy (Hepatology Research, 26: 287-292, 2003) 12. Tanaka J, et al., Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000 (Intervirology, 47: 32-40, 2004) 13. Consensus Statements on the Prevention and Management of Hepatitis B and Hepatitis C in the Asia-Pacific Region Journal of Gastroenterology and Hepatology,Volume 15 Number 8 August 2000-45 -
100-8916 1-2-2 03-5253-1111 URL http://www.mhlw.go.jp/ 113-0033 3-2-15 7F 03-3813-4077 URL http://www.vhfj.or.jp/ 113-8621 2-28-16 03-3942-6485 URL http://www.med.or.jp/kansen/ - 46 -